Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2024
0mins
Source: SeekingAlpha
New Appointments at Eliem Therapeutics: Eliem Therapeutics has appointed Brett Kaplan as COO and Nishi Rampal as Senior Vice President of Clinical Development, bringing significant experience from their previous roles in the biotech industry.
Background of New Executives: Kaplan previously raised $250 million for epigenetic research at Chroma Medicine, while Rampal led clinical development strategies at Horizon Therapeutics before its acquisition by Amgen.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
